Sanofi SA (SNY) reports a 7% revenue increase, with significant contributions from DUPIXENT and new product launches, despite ...

Shares rose after a jump in sales of the blockbuster Dupixent drug and robust pharmaceutical launches delivered higher ...

Sanofi (SNY) stock gains as the company posts a Q3 beat for 2025, driven mainly by Dupixent, an asthma therapy it markets ...

French drug major Sanofi reported a slight dip in third-quarter profit on Friday, even as sales rose, lifted by strong growth ...

Sanofi on Friday reported third-quarter profit that beat forecasts, boosted by demand for blockbuster asthma drug Dupixent, ...

Sanofi reported stronger than expected third-quarter profit on Friday, boosted by demand for blockbuster asthma drug Dupixent ...

Sanofi posted strong Q3 results amid currency challenges; discover key pipeline updates and growth prospects for investors.

Sanofi has dropped its respiratory syncytial virus (RSV) vaccine for toddlers after the candidate underperformed in a phase 3 ...

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...

Sales of Sanofi’s COVID-19 and flu vaccines fell 17% in the third quarter amid declining vaccination rates and pricing ...

Sanofi Q3 sales beat estimates on strong Dupixent and new drug demand; reaffirms 2025 outlook with double-digit EPS growth ...

Sanofi’s $1.7 billion rare disease bet from last year has delivered a phase 2 win. | Sanofi’s $1.7 billion rare disease bet ...